221 related articles for article (PubMed ID: 38164284)
1. Incidence of HER2-targeted antibody-drug conjugates-related cardiac events: a meta-analysis.
Liu F; Li H; Yin G; Pan Y
J Cancer; 2024; 15(1):90-102. PubMed ID: 38164284
[No Abstract] [Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis.
Fu Z; Liu J; Li S; Shi C; Zhang Y
EClinicalMedicine; 2023 Jan; 55():101795. PubMed ID: 36712893
[TBL] [Abstract][Full Text] [Related]
4. Incidence of antibody-drug conjugate-related fatigue in patients with breast cancer: A systematic review and meta-analysis.
Zhang H; Shen G; Yang P; Li J; Li Z; Liu Z; Wang M; Zhao F; Ren D; Liu Z; Zhao J; Zhao Y
Crit Rev Oncol Hematol; 2024 Apr; 196():104292. PubMed ID: 38403093
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer.
Pondé N; Ameye L; Lambertini M; Paesmans M; Piccart M; de Azambuja E
Eur J Cancer; 2020 Feb; 126():65-73. PubMed ID: 31923729
[TBL] [Abstract][Full Text] [Related]
6. Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment.
Ji C; Li F; Yuan Y; Zhang H; Bian L; Zhang S; Wang T; Li J; Jiang Z
Oncologist; 2023 Oct; 28(10):e859-e866. PubMed ID: 37218076
[TBL] [Abstract][Full Text] [Related]
7. Incidence of antibody-drug conjugates-related pneumonitis in patients with solid tumors: A systematic review and meta-analysis.
Zhu Z; Shen G; Li J; Qiu T; Fang Q; Zheng Y; Xin Y; Liu Z; Zhao F; Ren D; Zhao J
Crit Rev Oncol Hematol; 2023 Apr; 184():103960. PubMed ID: 36907365
[TBL] [Abstract][Full Text] [Related]
8. Adverse Event Profile Differences between Trastuzumab Emtansine and Trastuzumab Deruxtecan: A Real-world, Pharmacovigilance Study.
Liu F; Yin G; Xue S; Rehman FU; Liao D; Pan Y
J Cancer; 2023; 14(17):3275-3284. PubMed ID: 37928419
[No Abstract] [Full Text] [Related]
9. Efficacy and safety of trastuzumab deruxtecan in patients with solid tumors: a systematic review and meta-analysis of 3 randomized controlled trials.
Cai ZL; Yang HT; Huang T; Yu ZR; Ren N; Su JY; Lin XL; Zhou HR
Am J Cancer Res; 2023; 13(8):3266-3274. PubMed ID: 37693138
[TBL] [Abstract][Full Text] [Related]
10. Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis.
Soares LR; Vilbert M; Rosa VDL; Oliveira JL; Deus MM; Freitas-Junior R
ESMO Open; 2023 Aug; 8(4):101613. PubMed ID: 37481956
[TBL] [Abstract][Full Text] [Related]
11. Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape.
Adams E; Wildiers H; Neven P; Punie K
ESMO Open; 2021 Aug; 6(4):100204. PubMed ID: 34225076
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer.
Yang J; Han J; Zhang Y; Muhetaer M; Chen N; Yan X
Front Pharmacol; 2022; 13():924126. PubMed ID: 36160459
[No Abstract] [Full Text] [Related]
13. Incidence and risk of fatal adverse events in cancer patients treated with HER2-targeted antibody-drug conjugates: a systematic review and meta-analysis of randomized controlled trials.
Fu Z; Gao C; Xie J; Zhang C; Li S; Gu M; Shi C
BMC Cancer; 2023 Oct; 23(1):960. PubMed ID: 37817092
[TBL] [Abstract][Full Text] [Related]
14. The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan.
Schreiber AR; O'Bryant CL; Kabos P; Diamond JR
Expert Rev Anticancer Ther; 2023; 23(10):1061-1069. PubMed ID: 37742278
[TBL] [Abstract][Full Text] [Related]
15. HER2-targeted regimens after prior trastuzumab for patients with HER2-positive unresectable, locally advanced or metastatic breast cancer: a network meta-analysis of randomized controlled trials.
Li X; Wu S; Zhang L; Zhu J; Xu B
Ann Transl Med; 2020 Dec; 8(24):1634. PubMed ID: 33490146
[TBL] [Abstract][Full Text] [Related]
16. Pharmacovigilance Analysis of Heart Failure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer.
Waliany S; Caswell-Jin J; Riaz F; Myall N; Zhu H; Witteles RM; Neal JW
JACC CardioOncol; 2023 Feb; 5(1):85-98. PubMed ID: 36875913
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Tamura K; Tsurutani J; Takahashi S; Iwata H; Krop IE; Redfern C; Sagara Y; Doi T; Park H; Murthy RK; Redman RA; Jikoh T; Lee C; Sugihara M; Shahidi J; Yver A; Modi S
Lancet Oncol; 2019 Jun; 20(6):816-826. PubMed ID: 31047803
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study.
Curigliano G; Dunton K; Rosenlund M; Janek M; Cathcart J; Liu Y; Fasching PA; Iwata H
Ann Oncol; 2023 Jul; 34(7):569-577. PubMed ID: 37179020
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of antibody-drug conjugates in triple-negative and HER-2 positive breast cancer: A systematic review and meta-analysis of clinical trials.
Afzal F; Aiman W; Zahoor H; Bajwa AR; Kazmi SH; Anwar A; Anwar MY; Rashid S; Zubair H; Kashif T; Ashar Ali M
Breast Dis; 2023; 42(1):121-136. PubMed ID: 37125539
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and cost-effectiveness of trastuzumab emtansine in women with HER2-positive locally advanced or metastatic breast cancer: A systematic review and meta-analysis.
Yeh Y; Chen C; Ko Y
J Cancer Res Ther; 2022; 18(4):1061-1072. PubMed ID: 36149162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
